Skip to main content

Table 3 Multivariable hazard ratios (HR) and 95% confidence intervals (CI) of association between weight change categories and incident CHD: Tehran Lipid and Glucose Study, Iran, 1999–2018

From: Weight change and risk of cardiovascular disease among adults with type 2 diabetes: more than 14 years of follow-up in the Tehran Lipid and Glucose Study

  Model 1 Model 2
HR (95% CI) P-value HR (95% CI) P-value
Weight change categories
 Lost > 5% 1.19 (0.83–1.71) 0.334 1.14 (0.79–1.65) 0.471
 Lost 3% to 5% 0.86 (0.55–1.36) 0.526 0.76 (0.48–1.20) 0.238
 Stable (± 3%) Reference   Reference  
 Gained 3% to 5% 0.63 (0.37–1.08) 0.096 0.66 (0.38–1.15) 0.141
 Gained > 5% 0.62 (0.41–0.94) 0.026 0.61 (0.40–0.93) 0.021
Age, year 1.04 (1.03–1.05)  < 0.001 1.04 (1.02–1.05)  < 0.001
Women (men as reference) 0.92 (0.70–1.22) 0.569 0.82 (0.59–1.13) 0.216
BMI, kg/m2    0.99 (0.96–1.02) 0.423
Educational level, years
 > 12    Reference  
 6–12    0.91 (0.50–1.66) 0.768
 < 6    0.92 (0.51–1.69) 0.796
Current smoker, yes    1.73 (1.06–2.83) 0.028
GLD use, yes    1.75 (1.27–2.41) 0.001
Family history of premature CVD, yes    1.08 (0.76–1.52) 0.672
Hypertension, yes    1.63 (1.22–2.19) 0.001
Hypercholesterolemia, yes    2.09 (1.43–3.05)  < 0.001
CKD, yes    0.76 (0.55–1.05) 0.099
FPG, mmol/L    1.03 (0.99–1.08) 0.139
  1. Model 1: adjusted for age and sex. Model 2: Model 1 + further adjusted for BMI, educational level, current smoking (at first follow-up), GLD use (at baseline or first follow-up), family history of premature CVD, hypertension, hypercholesterolemia, CKD, and FPG
  2. CHD coronary heart disease, BMI body mass index, GLD glucose-lowering drugs, CVD cardiovascular disease, CKD chronic kidney disease, FPG fasting plasma glucose